AP-4-mediated axonal transport controls endocannabinoid production in neurons.
Alexandra K DaviesJulian Emanuel AlecuMarvin ZieglerCatherine G VasilopoulouFabrizio MerciaiHellen JumoWardiya Afshar SaberMustafa SahinDarius Ebrahimi-FakhariGeorg H H BornerPublished in: Nature communications (2022)
The adaptor protein complex AP-4 mediates anterograde axonal transport and is essential for axon health. AP-4-deficient patients suffer from a severe neurodevelopmental and neurodegenerative disorder. Here we identify DAGLB (diacylglycerol lipase-beta), a key enzyme for generation of the endocannabinoid 2-AG (2-arachidonoylglycerol), as a cargo of AP-4 vesicles. During normal development, DAGLB is targeted to the axon, where 2-AG signalling drives axonal growth. We show that DAGLB accumulates at the trans-Golgi network of AP-4-deficient cells, that axonal DAGLB levels are reduced in neurons from a patient with AP-4 deficiency, and that 2-AG levels are reduced in the brains of AP-4 knockout mice. Importantly, we demonstrate that neurite growth defects of AP-4-deficient neurons are rescued by inhibition of MGLL (monoacylglycerol lipase), the enzyme responsible for 2-AG hydrolysis. Our study supports a new model for AP-4 deficiency syndrome in which axon growth defects arise through spatial dysregulation of endocannabinoid signalling.
Keyphrases
- transcription factor
- spinal cord injury
- quantum dots
- spinal cord
- optic nerve
- healthcare
- end stage renal disease
- public health
- case report
- mental health
- induced apoptosis
- drug delivery
- prognostic factors
- oxidative stress
- early onset
- cancer therapy
- signaling pathway
- social media
- cell proliferation
- smoking cessation
- peritoneal dialysis
- replacement therapy
- amino acid
- health promotion